Content
Researchers at Mayo Clinic are making strides in detecting a rare and deadly heart condition called arrhythmogenic right ventricular cardiomyopathy (ARVC) much earlier than ever before. This genetic disease causes the proteins that hold heart cells together to weaken, eventually leading to scar tissue and fat replacing healthy muscle. Because of this, the heart's strength diminishes silently, with many people only realizing they have it when a severe symptom like sudden collapse during exercise occurs. Often, by the time the diagnosis is made, the heart is already damaged, increasing the risk of heart failure, the need for transplant, or sudden death.
Dr. Peter Noseworthy, who leads the Division of Heart Rhythm Services at Mayo Clinic, and genetic cardiologist Dr. John Giudicessi have teamed up to tackle this problem head-on. Their goal is to shift from reacting to these heart problems later on, to spotting and possibly preventing them much earlier. Dr. Noseworthy focuses on using digital tools and AI to pick up heart rhythm issues sooner, while Dr. Giudicessi studies how genetic mutations affect disease development, especially those inherited.
The duo utilized Mayo Clinic's Research Data Atlas, a massive resource combining genetic, clinical, and biospecimen information collected over decades. They zeroed in on individuals carrying mutations in the PKP2 gene, the most common genetic culprit in ARVC. Even though about one in every 2,000 people has this mutation, not everyone develops the disease. The challenge lies in figuring out who will and catching it early enough to make a difference.
To crack this, the researchers used an AI model developed by cardiologist Ammar Killu and his team, which analyzed electrocardiograms (ECGs) from patients with PKP2 mutations. The AI detected subtle, early changes in heart rhythms that humans might miss, offering a potential window for earlier diagnosis. This tech not only helps identify individual cases but also enables patterns to emerge across broader populations, which could transform early detection on a large scale.
Building on these findings, Drs. Noseworthy and Giudicessi gave smartwatches to participants showing early signs of the disease. These devices monitor daily activity since intense exercise can speed up disease progression, while small lifestyle tweaks might slow it down. Meanwhile, they're exploring gene therapy aimed at restoring the faulty PKP2 gene, a promising but still experimental approach to halt the disease's advance.
This work is part of a bigger vision at Mayo Clinic called Precure, which focuses on predicting and preventing serious diseases before they cause harm. Using tools like the Research Data Atlas, researchers can identify risk factors earlier and intervene sooner. For Drs. Noseworthy and Giudicessi, it's not just about one study — they're helping build the framework for a future where medicine catches diseases earlier, improving outcomes for many.
